STING1 and melanoma: Furthermore, MSA‐2 induced durable antitumor immunity and demonstrated strong synergy with anti‐PD‐1 in multiple tumor models, including B16‐F10 melanoma, CT26 colorectal, MC38 colorectal, and LL‐2 lung cancer, reinforcing its potential as a clinically relevant STING‐mediated immunotherapy.